Company intelligence / Profile preview

Exelead

Indianapolis, Indiana, United States

Ownership: Private
Employees: ~153
Development stage: Other

Overview

Exelead supports clinical and commercial production of lipid nanoparticle (LNP) and complex sterile injectable formulations, providing CDMO services for mRNA therapeutics and other advanced modalities including fill-finish, with scale-up supported by its parent, MilliporeSigma (Merck KGaA, Darmstadt, Germany). As a CDMO, Exelead does not pursue its own therapeutic programs but provides manufacturing for client products across various modalities and indications. It offers more than 10 years of experience in pre-clinical to commercial manufacturing.

Modalities: Lipid nanoparticle delivery therapyPEGylated formulationBiologicPeptidesProteinsSmall moleculemRNA-based drugs
Industry: Contract Manufacturing Organization

Partnerships

Merck KGaA, Darmstadt, Germany (parent/owner)

Beyond the preview

Go deeper on Exelead.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exelead.

Explore the full profile